Research progress on clinical treatment and innovative therapy of osteosarcoma

doi:10.3760/cma.j.issn.1007-1245.2023.09.004

Abstract

Abstract:

Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high tendency to metastasize, the underlying mechanism of which is still largely unknown. Clinical treatment of OS has a poor prognosis, and improving the survival rate in patients with OS remains a challenge. In recent years, with the development of molecular biology and tissue bioengineering, treatment methods have also made rapid progress, especially in the aspect of comprehensive limb salvage therapy, which significantly improves the postoperative quality of life and 5-year survival rate in patients with malignant tumors. This article reviews the surgical method, chemotherapy, and immunotherapy of OS, to provide reference for the current clinical treatment of OS.

Key words:

Osteosarcoma, Clinical treatment, Prognosis

摘要：

骨肉瘤（osteosarcoma，OS）是一种发生在骨组织中的高度恶性肿瘤，具有很高的转移倾向，其潜在机制在很大程度上仍不清楚。OS临床治疗预后较差，提高OS患者的生存率仍然是一个挑战。近年来，随着分子生物学和组织生物工程的发展，治疗方法也取得了迅速的进步，特别是在综合保肢治疗方面，显著提高了术后生活质量，提高了恶性肿瘤患者的5年生存率。本文对OS从手术、化学疗法和免疫疗法等方面进行综述，为当前OS的临床治疗提供参考。

关键词:

骨肉瘤, 临床治疗, 预后

Zhan Zeyu, Lin Sien, Wei Bo.

Research progress on clinical treatment and innovative therapy of osteosarcoma [J]. International Medicine and Health Guidance News, 2023, 29(9): 1197-1200..

詹泽宇林思恩魏波.

骨肉瘤临床治疗现状与创新疗法研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1197-1200..

References

[1] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1):89-99. DOI: 10.1016/j.pharmthera.2012.09.003.
[2] Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma[J]. N Engl J Med, 2021, 385(22):2066-2076. DOI: 10.1056/NEJMra2103423.
[3] Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols[J]. J Clin Oncol, 2003, 21(10):2011-2018. DOI: 10.1200/JCO.2003.08.132.
[4] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3):776-790. DOI: 10.1200/JCO.2002.20.3.776.
[5] Mustafa M, Iftikhar H, IIIzam E, et al. Osteosarcoma: current treatment trends and outcome[J]. IOSR Journal of Dental and Medical Sciences, 2018, 17(11): 32-38. DOI:10.9790/0853-1711023238.
[6] Hattinger CM, Patrizio MP, Fantoni L, et al. Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies[J]. Cancers (Basel), 2021, 13(12):2878. DOI: 10.3390/cancers13122878.
[7] Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma[J]. Clin Orthop Relat Res, 1980(153):106-120.
[8] Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases[J]. Ann Surg Oncol, 2014, 21(1):263-268. DOI: 10.1245/s10434-013-3210-4.
[9] Jauregui JJ, Nadarajah V, Munn J, et al. Limb salvage versus amputation in conventional appendicular osteosarcoma: a systematic review[J]. Indian J Surg Oncol, 2018, 9(2):232-240. DOI: 10.1007/s13193-018-0725-y.
[10] Odri GA, Tchicaya-Bouanga J, Yoon DJY, et al. Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers[J]. Cancers (Basel), 2022, 14(2):360. DOI: 10.3390/cancers14020360.
[11] Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy[J]. Nat Rev Endocrinol, 2017, 13(8):480-491. DOI: 10.1038/nrendo.2017.16.
[12] Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs[J]. Cancer Lett, 2021, 500:1-10. DOI: 10.1016/j.canlet.2020.12.024.
[13] Peng Z, Li M, Wang Y, et al. Self-assembling imageable silk hydrogels for the focal treatment of osteosarcoma[J]. Front Cell Dev Biol, 2022, 10:698282. DOI: 10.3389/fcell.2022.698282.
[14] Benjamin RS. Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective[J]. Adv Exp Med Biol, 2020, 1257:1-10. DOI: 10.1007/978-3-030-43032-0_1.
[15] Zheng C, Tang F, Min L, et al. PTEN in osteosarcoma: recent advances and the therapeutic potential[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2):188405. DOI: 10.1016/j.bbcan.2020.188405.
[16] Yang D, Xu T, Fan L, et al. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis[J]. J Exp Clin Cancer Res, 2020, 39(1):201. DOI: 10.1186/s13046-020-01670-3.
[17] Rabelo ACS, Borghesi J, Noratto GD. The role of dietary polyphenols in osteosarcoma: a possible clue about the molecular mechanisms involved in a process that is just in its infancy[J]. J Food Biochem, 2022, 46(1):e14026. DOI: 10.1111/jfbc.14026.
[18] Smrke A, Anderson PM, Gulia A, et al. Future directions in the treatment of osteosarcoma[J]. Cells, 2021, 10(1):172. DOI: 10.3390/cells10010172.
[19] Lettieri CK, Appel N, Labban N, et al. Progress and opportunities for immune therapeutics in osteosarcoma[J]. Immunotherapy, 2016, 8(10):1233-1244. DOI: 10.2217/imt-2016-0048.
[20] Wang Z, Li B, Ren Y, et al. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities[J]. Front Immunol, 2016, 7:353. DOI: 10.3389/fimmu.2016.00353.
[21] Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy[J]. Nature, 2019, 574(7776):45-56. DOI: 10.1038/s41586-019-1593-5.
[22] Corre I, Verrecchia F, Crenn V, et al. The osteosarcoma microenvironment: a complex but targetable ecosystem[J]. Cells, 2020, 9(4):976. DOI: 10.3390/cells9040976.
[23] Yoshida K, Okamoto M, Sasaki J, et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells[J]. BMC Cancer, 2020, 20(1):25. DOI: 10.1186/s12885-019- 6499-y.
[24] Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: where do we go from here?[J]. Pediatr Blood Cancer, 2018, 65(9):e27227. DOI: 10.1002/pbc.27227.
[25] Wang L, Mei Q, Xie Q, et al. A comparative study of Mesenchymal Stem Cells transplantation approach to antagonize age-associated ovarian hypofunction with consideration of safety and efficiency[J]. J Adv Res, 2021, 38:245-259. DOI: 10.1016/j.jare.2021.09.001.
[26] Hammad M, Cornejo YR, Batalla-Covello J, et al. Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model[J]. Mol Ther Oncolytics, 2020, 18:326-334. DOI: 10.1016/j.omto.2020.07.002.
[27] Yu W, Zhu J, Wang Y, et al. A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep[J]. Oncotarget, 2017, 8(24):39833-39848. DOI: 10.18632/oncotarget. 16243.
[28] Tan G, Xu J, Yu Q, et al. The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: a systematic review of in vitro experiment and animal model reports[J]. Photodiagnosis Photodyn Ther, 2022, 40:103093. DOI: 10.1016/j.pdpdt.2022. 103093.
[29] Barani M, Mukhtar M, Rahdar A, et al. Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma[J]. Biosensors (Basel), 2021, 11(2):55. DOI: 10.3390/bios11020055.
[30] Yu W, Ye M, Zhu J, et al. Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma[J]. Nanomedicine, 2018, 14(4):1099-1110. DOI: 10.1016/j.nano.2018.02.005.